Understanding the Molecular Level Interactions of Cancer Inhibitor Imatinib with Human Fibroblast Growth Factor-1 by Modi, Tulsi
Western Kentucky University
TopSCHOLAR®
Masters Theses & Specialist Projects Graduate School
5-2015
Understanding the Molecular Level Interactions of
Cancer Inhibitor Imatinib with Human Fibroblast
Growth Factor-1
Tulsi Modi
Western Kentucky University, tulsi.modi478@topper.wku.edu
Follow this and additional works at: http://digitalcommons.wku.edu/theses
Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Chemistry
Commons
This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Masters Theses & Specialist Projects by
an authorized administrator of TopSCHOLAR®. For more information, please contact topscholar@wku.edu.
Recommended Citation
Modi, Tulsi, "Understanding the Molecular Level Interactions of Cancer Inhibitor Imatinib with Human Fibroblast Growth Factor-1"









UNDERSTANDING THE MOLECULAR LEVEL INTERACTIONS OF CANCER 












The Faculty of the Department of Chemistry 
Western Kentucky University 












In Partial Fulfillment 
Of the Requirements for the Degree 


















This thesis appears in its current form due to the assistance and guidance of several 
people. I would therefore like to offer my sincere thanks to all of them.  
I would like to start with the person who made the biggest difference in my life, my 
research advisor Dr. Rajalingam Dakshinamurthy. I express my sincere gratitude for his 
continuous support, guidance, motivation, patience, enthusiasm, and immense 
knowledge during my graduate studies at Western Kentucky University. Without his 
assistance and dedicated involvement in every step throughout the process, this 
dissertation would have never been accomplished. I would like to sincerely thank my 
committee members, Dr. Cathleen Webb and Dr. Rui Zhang for their encouragement, 
insightful comments and willingness to take time to discuss my research. 
Most importantly, none of this could have happened without my parents, Mahesh 
and Bhavana Modi. I don’t imagine a life without their love and blessings. Thank you 
for showing faith in me and giving me liberty to choose what I desired. I also thank my 
brother, Mr. Vishal Modi and sister-in law, Mrs. Bhumi Modi for always encouraging 
me throughout this journey. 
In addition, I acknowledge Dr. Krystal Hamorsky from Owensboro Cancer Research 
Program, University of Louisville for her assistance and guidance in carrying out 
biacore experiments. I also extend my deepest gratitude to Dr. Chad Snyder, Mrs. 
Naomi Rowland, Dr. John Andersland, Dr. Quentin Lineberry, and Mrs. Pauline Norris 
for all their advice and help during my journey at WKU. I also thank Mrs. Alicia 
Pesterfield for arranging, providing and ordering all the necessary chemicals and 
  
 
solvents on time. I am also grateful to Mrs. Haley Smith and Mrs. Phyllis Townsend for 
all their administrative help. 
I also thank all my lab members including Filani Oluwadamilola, Sarah Tockstein, 
Hitesh Waghwani, Jason Payne, William Hamilton and several gatton students for all 
their help and cheerful moments. I would also like to thank Rammohan Paripelly for his 
initial training to get a hands-on expertise on various methods and instrumental 
techniques used for this study.  
 
  
  vi 
CONTENTS 
1. INTRODUCTION ....................................................................................................... 1 
1.1. Protein Export ..................................................................................................... 1 
1.2. Signal Sequence-Less Proteins ........................................................................... 3 
1.3. Non-classical export of hFGF-1 ......................................................................... 3 
1.4. The Function and Structure of FGFs .................................................................. 6 
1.5. FGFs and Heparin Binding ............................................................................... 10 
1.6. FGF Receptor(s) – FGF Interaction(s) ............................................................. 12 
1.7. hFGF-1 and Imatinib Interaction ...................................................................... 15 
2. MATERIALS AND METHODS .............................................................................. 17 
2.1. Materials ........................................................................................................... 17 
2.2. Expression of hFGF-1....................................................................................... 18 
2.3. Purification of hFGF-1 ..................................................................................... 19 
2.4. Characterization of hFGF-1 .............................................................................. 21 
2.5. Steady State Fluorescence ................................................................................ 21 
2.6. Proteolytic Digestion Assay ............................................................................. 22 
2.7. Surface Plasmon Resonance (SPR) Analysis ................................................... 22 
3. RESULTS AND DISCUSSION ............................................................................... 23 
3.1. Expression and Purification of hFGF-1 ............................................................ 23 
3.2. hFGF-1 is Stabilized by Imatinib Binding........................................................ 27 
3.2.1. Steady State Fluorescence ......................................................................... 27 
3.2.2. Proteolytic Digestion ................................................................................. 29 
3.2.3. Surface Plasmon Resonance (SPR) ........................................................... 31 
4. CONCLUSION ......................................................................................................... 34 
5. FUTURE WORK ...................................................................................................... 35 
6. REFERENCES .......................................................................................................... 36 
7. ABBREVIATIONS ................................................................................................... 42 
  
  vii 
LIST OF FIGURES 
 
Figure 1: Overview of sorting of nuclear-encoded proteins in eukaryotic cells.. ............. 2 
Figure 2: Proposed mechanism for the non-classical release of hFGF-1 .......................... 5 
Figure 3: Three-dimensional structure of hFGF-1. ........................................................... 9 
Figure 4: Structure of heparin ......................................................................................... 11 
Figure 5: Structural units of fibroblast growth factor receptor. ...................................... 13 
Figure 6: Schematic representation of the mechanism of signal transduction ................ 14 
Figure 7: Represents the structure of imatinib ................................................................ 16 
Figure 8: Schematic illustrating expression and purification of hFGF-1. ....................... 20 
Figure 9: Heparin sepharose affinity column .................................................................. 24 
Figure 10: SDS-PAGE depicting the expression and purification of hFGF-1 ................ 24 
Figure 11: Size-exclusion chromatography profile of hFGF-1 using FPLC ................... 25 
Figure 12: Reverse phase HPLC profile for purified hFGF-1 ......................................... 25 
Figure 13: Electron-spray mass spectrum of hFGF-1 ..................................................... 26 
Figure 14: Represents the emission spectra of hFGF-1 .................................................. 28 
Figure 15: Represents the thermal unfolding of hFGF-1. ............................................... 28 
Figure 16: Limited trypsin digestion monitored by SDS-PAGE .................................... 30 
Figure 17: Representative measurements of imatinib binding to hFGF-1 by SPR. ........ 33 
 
  
  viii 
LIST OF TABLES 
 
Table 1: List of all the supplies required for the study .................................................... 17 
Table 2: The various primary structural parameters of hFGF-1 ..................................... 21 
  
  ix 
UNDERSTANDING THE MOLECULAR LEVEL INTERACTIONS OF CANCER 
INHIBITOR IMATINIB WITH HUMAN FIBROBLAST GROWTH FACTOR-1  
 
Tulsi Modi    May 2015           Pages: 42 
  
Directed by: Dr. Rajalingam Dakshinamurthy 
 
Department of Chemistry              Western Kentucky University 
 
Fibroblast growth factors (FGFs) lack signal sequences, and are exported through 
endoplasmic reticulum (ER)-Golgi-independent non-classical routes. FGFs work as 
modulators of various cellular activities like mitosis, differentiation, survival etc. 
Among the FGF family, which comprises of 23 different heparin proteins, human FGF-1 
(hFGF-1), a potent angiogenic factors are one of the targets in cancer inhibition, as they 
are involved in blood vessel formation in tissues. There has been intensive research 
directed at the development of drugs that could effectively inhibit angiogenesis. In this 
context, the purpose of this study is to fully understand the molecular principles essential 
to determine probability of inhibition of hFGF-1 signaling transduction by imatinib. 
Imatinib, a 2-phenyl amino pyrimidine derivative is a tyrosine kinase inhibitor with 
antineoplastic activity. Imatinib binds to the intracellular pocket located within tyrosine 
kinases and inhibit the downstream cell proliferation events, but the exact molecular 
mechanism is still elusive. In this study, expression of hFGF-1 in recombinant E. coli 
was carried out, and the expressed protein was purified using heparin affinity column 
chromatography. The structural interactions governing imatinib-hFGF-1 interaction was 
studied by monitoring its stability, conformation and binding affinity by equilibrium 
unfolding using steady state fluorescence and proteolytic digestion assay. These data 
show that imatinib binds to hFGF-1 and enhances its thermal stability and solvent 
accessibility. In addition, biacore analysis was carried out to determine the binding 




1.1. Protein Export 
Protein transport across the ER membrane in eukaryotes is an early and decisive step 
in the biosynthesis of many proteins [1]. Proteins, which are produced by the cell, must 
reach their correct locations for the cell to function properly. Proteins which are 
synthesized in the cell need to be delivered to the proper targeting (or) protein sorting 
encompasses two very different kind of process [2]. 
Targeting of water soluble protein occurs through the translocation of the protein 
across the membrane into the aqueous organelle. In the case of membrane proteins, 
targeting leads to insertion of the protein into the lipid bilayer of the membrane [2]. In 
the second step, which is the primary sorting process, proteins are sorted to the 
endoplasmic reticulum (ER), mitochondria, chloroplast, peroxisomes and the nuclease. 
Both types of proteins (soluble and membrane proteins) use the same machinery for 
translocation across the membrane, a protein-conducting channel with hydrophilic 
interior. This channel, in contrast to those channels that transport ions and small 
molecules, has the unusual property of being able to open in two orientations; 
perpendicular to the plane of the membrane to allow a polypeptide segment across, and 
within, the membrane to allow a hydrophobic transmembrane segment of a membrane 
protein to exit laterally into the lipid phase [3,4,5]. 
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1.2. Signal Sequence-Less Proteins 
Proteins destined for the classical secretion pathway (e.g. serum proteins such as 
immunoglobulins) typically contain N-terminal signal peptides that mediate membrane 
translocation into the lumen of the endoplasmic reticulum followed by the ER/Golgi-
dependent transport to the cell surface [2]. By contrast, a large group of exported 
proteins do not have signal peptide [5]. 
The ability of these signal sequence-less proteins to undergo non-classical release 
attracted considerate attention since they play roles in important physiological processes 
such as cell growth and differentiation, inflammation and angiogenesis [6]. Among 
those are important disease related proteins such as interleukin 1α and 1β, fibroblast 
growth factors (FGF) 1 and 2, infection-related cell surface markers of Leishmania 
parasites (HASP family), viral proteins such as Herpes simplex tegument protein vp22, 
etc. Consistently, these secretory proteins do not localize to the endoplasmic reticulum 
or the Golgi apparatus, and do not contain ER/Golgi-specific post-translational 
modification such as glycosylation. Importantly, inhibitors of the classical pathway 
including brefeldin A do not interfere with secretion of these proteins [7] (Fig.1).  
1.3. Non-classical export of hFGF-1 
Human fibroblast growth factor-1 (hFGF-1) is a prototypical member of the FGF 
family. Four kinase transmembrane receptors (FGFR1-4) and cell surface heparin sulfate 
proteoglycans mediate FGFs biological effects. Most members of the family therefore 
possess classical signal sequence but hFGF-1 and hFGF-2 do not have such sequences 
and thus are released by a novel secretory mechanism. The existence of hFGF-1 and 
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hFGF-2–specific secretion pathways might represent a protective mechanism developed 
in the course of evolution, which might be related to their high mitogenic potential and 
widespread expression [8]. 
hFGF-1, a close relative of hFGF-2, is believed to be secreted by a mechanism 
distinct from hFGF-2 export. hFGF-1 release can be triggered under stress condition 
such as heat shock treatment, an experimental condition without any impact on hFGF-2 



















Figure 2: Proposed mechanism for the non-classical release of hFGF-1. Two 
intracellular proteins, S100A13 and Syt1 have been shown to associate with the latent 
hFGF-1 homodimer in in the cytoplasm. Both S100A13 and p40-Syt1 are calcium 





























Prudovsky et al., employing a real-time analysis of various hFGF-1-expressing 
cell lines, have demonstrated that heat shock treatment triggers the redistribution of 
hFGF-1 along with other components of the S100 release complex forming a diffuse 
cytoplasmic pattern into a population that accumulates at the inner leaflet of the plasma 
membrane [13,14]. This subcellular redistribution of hFGF-1 along with other 
components of the release complex has been interpreted as the initial step of heat shock-
triggered hFGF-1 secretion. Even though it remains elusive as to how the hFGF-1 
containing hetero-oligomeric complex gets translocated across the plasma membrane, 
the data clearly suggests that the overall process of hFGF-1 secretion does not involve 
intracellular vesicles but rather relies on a direct transport mechanism at the level of the 
plasma membrane [5,10]. 
1.4. The Function and Structure of FGFs 
FGFs are essential signaling molecules for the regulation of a variety of 
physiological processes including embryonic growth, development, cell proliferation, 
differentiation and angiogenesis [11,12]. FGFs are believed to elicit the biological 
response by binding to two classes of receptors on the cell surface [13–15]. One 
comprises of transmembrane receptor with intrinsic protein kinase activity. The second 
class of receptors includes a family of cell surface heparan sulfate proteoglycans 
(HSPG) that bind FGF with low affinity [16–18]. There is a lot of debate on the role of 
the low affinity cell surface receptors in the FGF-mediated biological activities. A dual 
receptor model for FGF action has been proposed in which it is suggested that binding 
of heparin-like proteoglycans induces FGF oligomerization, which is crucial for 
subsequent binding of the growth factor to the high affinity receptor(s) [19]. However, 
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several recent studies have indicated that heparin binding may not be mandatory for the 
cell proliferation activity of FGFs [20–22]. 
The FGF family consists of at least 22 related members that have been identified 
(FGF1-FGF22). These proteins share a common core of around 140 amino acids. The 
amino acid sequences of FGFs isolated from various sources are well conserved. 28 
residues are highly conserved and 6 residues are invariant [23]. 10 of the highly 
conserved residues are involved in FGF receptor binding [13]. Acidic FGF (hFGF-1) 
and basic FGF (hFGF-2) are considered prototypes of the whole family [13,24,25]. Full-
length FGF-1 and FGF-2 contain about 154 amino acids and they lack disulfide bonds 
[9,13]. Both hFGF-1 and hFGF-2 contain a nuclear localization sequence (NLS) located 
near the amino-terminus of the proteins [26–32]. However, the function of NLS 
sequence in the FGF prototypes appears to be restricted since the initiation of translation 
at the AUG start sites yield proteins which remain associated in the cytosol [26,27]. This 
aspect is critical for the activity of the FGF prototypes as exogenous protein, since it is 
unlikely that the nuclear-associated FGF can be expected to participate in a pathway of 
secretions. The NLS sequences play a crucial role in maintaining the structural integrity 
of FGF-1 that is required for optimal binding to and activation of its cell surface receptor 
[32].  
The first 23 N-terminal residues do not play any significant role in the cell 
proliferation activity of hFGF-1 [13,33]. No significant differences in stability and 
biological properties have been detected among the different truncated forms of FGF-1 
[33]. However, deletion of residues 23 to 26 (Lys-Lys-Pro-Lys), plus replacing the 
highly conserved residues of Leu27 by Met increases the heparin binding affinity and 
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ability to trigger early mitogenic events such as intracellular receptor-mediated tyrosine 
phosphorylation but fails to induce DNA synthesis and cell proliferation [32]. As the 
Lys-Lys-Pro-Lys-sequence bears similarity to the NLS sequence (NYKKPKL), it was 
proposed that this stretch of residues (23-26) could be partly responsible for the 
translocation of the receptor protein (FGFR) to the nucleus [32]. 
The 3-D structures of FGFs are available [12,34–36]. All these proteins form a -
trefoil structure with a pseudo 3-fold-axis of symmetry. The crystal and solution 
structures of hFGF-1 have been determined at high resolution. Both results indicate that 
hFGF-1 is an all -sheet protein consisting of 12 -strands arranged into a -trefoil 
architecture [12,33–35,37]. 10 of the -strands are paired to form hairpin structures (-
straind II- -straind III, -straind IV- -straind V, -straind VI- -straind VII, -straind 
VIII- -straind IX, -straind X- -straind XI). The -trefoil structure contains 4 stranded 
-sheets in which -strand X and -strand XI forms the heparin-binding site (Fig. 3). 
Recent NMR studies revealed that the residues 120-142, constitute the primary heparin-




Figure 3: Three-dimensional structure of hFGF-1. The protein is bereft of disulfide 



































1.5. FGFs and Heparin Binding 
The binding interactions between FGFs and heparan sulfate proteoglycans were 
found on the cell surface and in the extracellular matrix [39]. Owing to the strong 
affinity of FGFs for heparin, it is believed that the glycosaminoglycan has a 
physiological role [40]. Binding to heparin is shown to stabilize FGFs and thereby 
diminishing their inactivation by heat, acid [41,42], proteolysis [43,44] and mild 
oxidation in vitro [45]. Stabilization is particularly relevant for hFGF-1, which is shown 
to exhibit an unfolding transition at physiological temperatures in the absence of 
polyanions, such as heparin [42,42]. The heparin polymer is generated from disaccharide 
repeat units consisting of D-glucosamine and L-iduronic acid joined by 1-4 linkages 
[46,47] (Fig. 4). A minimal saccharide sequence required for hFGF-2 binding consists of 
five monosaccharide units, with N-sulfate groups, and a single iduronic acid with 2-O-
sulfate residue but no 6-O-sulfate. However, by contrast, a sequence of about twice this 










Figure 4: Structure and prevalent sequences in regular regions of heparin composed by 


















X-ray and NMR structures of FGFs in the presence of the structural analogues of 
heparin revealed that the glycosaminoglycan binding site is located in the C-terminal 
region spanning residues 130-154 [34,35].  
1.6. FGF Receptor(s) – FGF Interaction(s) 
The diverse activities of FGFs are mediated by binding to high-affinity receptor 
tyrosine kinases [49]. The FGF receptor family comprises 4 transmembrane tyrosine 
receptors (FGFR1-FGFR4), which have been identified in humans [50–53]. Each of 
FGF receptor contains an extracellular ligand-binding region, a transmembrane helix 
domain, and an intracellular tyrosine kinase domain including a catalytic site and an 
ATP binding site [23,49,54] (Fig. 5). The homologies of human FGFR1- FGFR4 are in 
the range of 54-69% [55,56]. The tyrosine kinase domains are the most conserved 
regions. The ligand-binding region consists of domains (D1, D2 and D3).  
Between D1 and D2 domain there is a stretch of positively charged amino acids 
(called acid box, AB)  [50,51,57]. Site-directed mutagensis studies and the recent crystal 
structure data on the FGF-receptor complex have helped in the characterization of the 
ligand (FGF)-receptor (FGFR) interface [23,49,54,58–60]. The C-terminal region of the 
D3 domain has been shown to be important for ligand binding specificity [59].  
Dimerization of the extracellular domains leads trans-autophosphorylation on 
tyrosine residues. Phosphorylation of the tyrosine residues in the receptor either 
activates the intrinsic catalytic activity of the receptor or results in the recruitment of 




Figure 5: Schematic of FGFR. The receptor is composed of three main portions: the 
extracellular portion, a transmembrane domain, and a cytoplasmic tyrosine kinase 
domain. The extracellular ligand-binding contains three domains. The tyrosine kinase 












Figure 6: Schematic representation of the mechanism of signal transduction induced by 
hFGF-1. hFGF-1 binds to the extracellular (D2 and D3) domains of FGFR and induces 
dimerization of hFGF-1 monomers. Dimerization of receptor monomers upon ligand 
(FGFs) binding is likely to be a requisite for activation of the kinase domains, leading to 











1.7. hFGF-1 and Imatinib Interaction 
Different mechanisms are proposed for hFGF-1 receptor dimerization. However, 
models indicate that the D2 domains of FGF receptors are indispensable for the binding 
interactions to hFGF-1 and heparin molecules. Tyrosine kinase plays an important role 
in phosphate group transfer in a cell and also acts as a “on” and “off” switch in many 
cellular processes. Kinases can be in “on” positions and trigger unregulated growth of 
the cell which leads to cancer [62,63].  
Imatinib, a kinase inhibitor (Fig. 7) was one of the first cancer therapies to show 
potential for targeted action, and is often cited as a paradigm for research in cancer 
therapeutics [64]. Imatinib is currently used to treat Philadelphia chromosome-positive 
chronic myelogenous leukemia (Ph+ CML), gastrointestinal stromal tumors, and a 
number of other malignancies [65,66]. Cancer development is facilitated via a signaling 
cascade that begins with a phosphorylation event of subsequent proteins by BCR-Abl (a 
tyrosine kinase enzyme). Imatinib works by inhibiting BCR-Abl, thus preventing 
proliferation of cancer cells leading to their deaths by apoptosis [65,66]. Though 


















Since hFGF-1 mediated angiogenesis plays a crucial role in the progression and 
metastasis of cancer, there has been an intensive research directed at the development of 
drugs that could effectively inhibit angiogenesis. In this context, an attempt was made to 
understand the molecular interaction between imatinib with growth factor.  The 
structural interactions governing imatinib-hFGF-1 interaction were studied by 
investigating its stability, conformation and binding affinity using steady state 
fluorescence, proteolytic digestion assay and biacore respectively. Furthermore, the 
proposed research will shed light on the potential role of imatinib in growth factor 




2. MATERIALS AND METHODS 
2.1. Materials 
Reagent Catalog number Company 
Ammonium Sulfate AX1385-1 EMD Chemicals 
Ampicillin 0339 Amresco 
ß-mercatoethanol M3148 Sigma Aldrich 
Chloramphenicol C0378 Sigma Aldrich 
CM5 chip BR-100399 GE Healthcare 
Disodium hydrogen 
phosphate 
1.06573.0503 EMD Chemicals  
E. coli [BL21(DE3)] pLysS C6000-03 Invitrogen 
Glycerol GX0185-6 EMD Chemicals 
HBS-EP buffer (pH 7.4) BR100188 GE Healthcare 
Heparin sepharose resin 17-0998-01 GE Healthcare 




L.B Media  71753-6 Novagen 
SDS 7910 EMD Chemicals 
Sodium Chloride 3624-05 J.T. Baker 
Sodium dihydrogen 
phosphate 
SX0711-1 EMD Chemicals 
2,4,6-
Trichloroanisole (TCA) 
T6399 Sigma Aldrich 
Urea 4204-05 J.T. Baker 
Table 1: List of all the supplies required for the study with their respective catalog 









2.2. Expression of hFGF-1 
The expression vector pJExpress414 encoding the cDNA sequence of hFGF-1 was 
performed following essential procedure. hFGF-1 cDNA was transformed into the host 
cell Escherichia coli B21(DE3)pLysS for protein expression in high yields [67]. The 
gene sequences were optimized using DNA2.0 codon bias algorithm to maximize the 
yield of the proteins, prior to cloning [68]. 
Overnight 50 mL cultures of E. coli strain BL21(DE3)pLysS cells containing 
recombinant plasmid were diluted into 1L cultures of Luria broth (LB) containing 100 
µL/mL ampicillin and 35 µg/mL chloramphenicol and were incubated at 37°C at 150 
rpm until the absorbance was 0.6 at 600nm. 1 mL of the uninduced sample was collected 
at this point. Isopropylthio-ß-D-galactoside (IPTG) was then added to a final 
concentration of 1.0 mM to induce the expression of the target protein. Again, 1 mL of 
the induced sample was collected and the remaining cultures were collected by 
centrifugation at 6000 rpm for 20 minutes. Cell pellets were then resuspended in 30 mL 
1X PBS buffer. 1 mL sample was collected and the cells were lysed by ultrasonicator for 
60 seconds at the power level of 15 Ohms and the lysate was cleared by centrifugation. 
The expression of the protein (hFGF-1) was analyzed by SDS-PAGE. Protein samples of 
both un-induced and induced cultures were centrifuged and the settled pellets were 
dissolved in 8M urea followed by addition of 2X loading dye. The sample was then 
centrifuged and 20 µL of the supernatant of each sample was added to each well in the 
SDS gel and processed for 60 minutes at 180 Volts (Fig. 8). 
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2.3. Purification of hFGF-1 
Human acidic fibroblast growth factor is a heparin binding protein. The binding 
ability of hFGF-1 to heparin is retained even after deletion of the first 14 amino acids at 
the N-terminal of the protein. The binding affinity of hFGF-1 to heparin facilitates the 
purification of hFGF-1 from the cell crude lysate. The cells were harvested and lysed by 
sonication. The lysate was then cleared by centrifugation at 12,000 rpm for 3 minutes. 
The supernatant was then loaded on a heparin affinity column and incubated for 60 
minutes. hFGF-1 was purified by applying a stepwise NaCl gradient from 0.0 M, 0.65 
M, 0.85 M and 1.5 M NaCl in 10 mM phosphate buffer at pH 7.2 to the column. hFGF-1 
was found to elute out at 1.5 M NaCl (Fig. 8). The proteins eluted at various 
concentration of NaCl were analyzed by SDS-PAGE. The eluted protein was desalted in 
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2.4. Characterization of hFGF-1 
The amino acid sequence of hFGF-1 is given in Table 2. 
MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD 
QIQLQLSAES VHGEVYIKST ETGQYLAMDT DGLLYGSQTP 
NEECLFLERL EENHYNTYIS KKHAEKNWFV GLKKNGSCKR 
GPRTHYGQKA ILFLPPLPVS SD  
Table 2: The various primary structural parameters of hFGF-1 were obtained using a 
analysis tool called protparam. 
 
hFGF-1 obtained with 1.5 M NaCl was further purified by gel filtration on Superdex 
75 (Pharmacia) column by FPLC. Reverse phase HPLC was used to determine the purity 
of hFGF-1. Electro-spray mass spectrum was also performed to confirm the exact 
molecular weight of the purified protein. The yield of the purified hFGF-1 was 
quantified using UV-Vis spectroscopy. 
2.5. Steady State Fluorescence 
Fluorescence experiments were performed using PerkinElmer Spectro-fluorometer at 
5 nm resolution. The excitation and emission wavelengths were set at 280 and 394 nm 
respectively. Intrinsic fluorescence measurements were made at a protein concentration 
of 50µM in presence of 50 µM of imatinib using an excitation wavelength of 280 nm. 
The requisite temperature(s) in the thermal denaturation experiments was attained using 




2.6. Proteolytic Digestion Assay 
The limited proteolytic experiments on hFGF-1 and hFGF-1 - imatinib mixture (1:1) 
were carried out (at 25 ± 2 °C) using trypsin. Trypsin was used as a protease for the 
proteolytic digestion experiments. The trypsin digestion samples were collected at 
desired time intervals. A ~16 kDa band was used as a control to measure the uncleaved 
protein on SDS-PAGE.  
2.7. Surface Plasmon Resonance (SPR) Analysis 
Binding analysis was performed using BIAcore X1000 instrument. Experiments 
were performed at 25 °C with HBS-EP buffer (pH 7.4) as a running buffer and a flow-
rate of 20 µL/min. 10 µL of 25 µg/mL hFGF-1 in 1X HBS-EP buffer (pH 7.4) was used 
for immobilization (ΔRU ~4000) on a CM5 chip. For hFGF-1 – imatinib interaction, 
different concentrations of imatinib (6.25, 12.5, 25, 50 and 100 uM) in HBS-EP buffer 
were injected over the hFGF-1 sensor chip for 180 seconds to observe the association 
phase of the hFGF-1-imatinib interaction.  After each analyte injection, HBS-EP buffer 
was passed over the chip to monitor the dissociation phase. At the end of each sample 
injection, the sensor surface was fully regenerated by injection of 20 µL of 2.5 M NaCl. 







3. RESULTS AND DISCUSSION 
3.1. Expression and Purification of hFGF-1 
hFGF-1 used in the present study is a 154 amino acid polypeptide bereft of 
disulfide bonds [69,70]. Gel electrophoresis experiments confirmed the presence of the 
protein in soluble fraction of bacterial cell lysate. The purification was facilitated by 
using heparin sepharose affinity chromatography to separate hFGF-1 from other 
proteins. hFGF-1 was found to be bound to heparin quite strongly and the undesired 
proteins and other materials such as lipids from the loaded lysate were removed by 
extensively washing the resin with 10 mM phosphate buffer [71]. Purification was then 
carried out over NaCl gradient (from 0 to 1.5 M) (Fig 9). Collected fractions were then 
analyzed by SDS-PAGE. SDS-PAGE of the purified sample yielded an intense single 
band corresponding to a molecular mass of ~16 kDa (Fig 10). 
The yield of the purified hFGF-1 was quantified using UV-Vis spectroscopy and 
found to be about 20-25 mg/L culture. hFGF-1 obtained with 1.5 M NaCl was further 
purified by gel filtration on Superdex 75 (Pharmacia) column by FPLC (Fig. 11).  
Reverse phase HPLC was used to determine the purity of the purified hFGF-1 (Fig. 
12). The HPLC profile shows that the purified hFGF-1 is more than 95 %. The 
molecular weights of the plain hFGF-1 estimated by ESI-Mass exactly matches with the 






Figure 9: Purification of hFGF-1 using sodium chloride gradient in heparin column.  
Figure 10: SDS-PAGE depicting the expression and purification of hFGF-1 from E.coli. 
Lane M, represents the molecular weight standards; Lane 1, un-induced bacterial cells; 
Lane 2, induced bacterial cells; Lane 3, depicts soluble fraction; Lane 4, depicts 
insoluble fraction. Lanes 5-12 represents the SDS-Page fractions collected with buffer 
containing varying concentrations of sodium chloride. Lane 5, represents flow through; 
Lane 6, depicts protein bands contained in fraction eluted in 10 mM phosphate buffer; 
Lane 7, represents protein bands contained in fractions eluted in 0.8 M NaCl with 10 
mM phosphate buffer; Lanes 8-11, depicts protein bands contained in fractions eluted in 
10 mM phosphate buffer containing 1.5 M NaCl; Lane 12 depicts protein bands 





















Figure 12: Reverse phase HPLC profile for purified hFGF-1. Protein was eluted at 
~33.56 mins in a water and acetonitrile gradient. 
Figure 11: Size-exclusion chromatography profile of hFGF-1 using FPLC at room 
























Figure 13: Electron-spray mass spectrum of hFGF-1 shows expected molecular weight 





































3.2. hFGF-1 is Stabilized by Imatinib Binding 
3.2.1. Steady State Fluorescence 
hFGF-1 contains a single well conserved tryptophan at position 121 [72]. The 
aromatic amino acid tyrosine shows the emission peak at 308 nm when hFGF-1 is in 
native state [71,73,74]. However, when the protein is in denatured state, tryptophan peak 
is dominated at 350 nm [71,74]. These fluorescence features can be used to monitor the 
thermal denaturant unfolding of hFGF-1 (Fig. 14). Equilibrium thermal denaturation of 
hFGF-1 was performed to assess the conformational stability of hFGF-1 upon binding to 
imatinib (Fig. 15). The Tm (the temperature at which 50% of the molecules are in the 
native state) of the protein increases in the presence of the drug by about 6 °C (from 51 
°C to 57 °C), suggesting that thermodynamic stability of the protein is enhanced upon 













Figure 14: Represents the emission spectra of hFGF-1 in its native (green) and 
denatured (red) states.  Ratio of intensities 308/350: ~4 for native, properly folded and 
~1 for altered structure. 
Figure 15: Represents the thermal unfolding of hFGF-1 in the absence (red) and in the 
presence (blue) of imatinib.  The Tm (melting temperature of protein) value of the 
thermal induced unfolding of hFGF-1 estimated from the fluorescence experiment is 






















3.2.2. Proteolytic Digestion 
Limited proteolytic digestion is a popular technique to probe the protein-ligand 
interactions [75]. In principle, binding of a ligand/drug can potentially mask the 
cleavage sites in the protein substrate and these subtle differences in the cleavage 
patterns (between the free and the ligand/drug bound protein substrate) could be easily 
detected by SDS-PAGE analysis [75–77]. As hFGF-1 contains lots of arginine and 
lysine residues, we plan to determine the binding of imatinib to hFGF-1 using a limited 
trypsin technique. The experiment was carried out for hFGF-1 and the hFGF-1-imatinib 
mixture at 25 ± 2 °C using trypsin in a time-dependent manner. The uncleaved hFGF-1 
was measured using SDS-PAGE by comparing with the parent band intensity. SDS-
PAGE analysis of the tryptic digests of hFGF-1 obtained in the presence and absence of 
imatinib clearly reveals that the protein upon binding to the drug is more resistant to 
proteolytic cleavage (Fig. 16). The enhanced resistance of trypsin cleavage could be due 
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Figure 16: Limited trypsin digestion monitored by SDS-PAGE of hFGF-1 in the 
absence of (A) and presence (B) of imatinib. Lane C contained hFGF-1 in the absence 
of trypsin. Lanes 0-80 contained the trypsin digestion cleavage products obtained at 
various time periods of incubation with trypsin in the absence and presence of imatinib. 






















3.2.3. Surface Plasmon Resonance (SPR) 
Biacore is a technique that monitors molecular interactions in real time by measuring 
surface binding of unlabeled drug to protein-coated surfaces [78,79]. It responds to 
changes in the concentration of molecules at a sensor surface as molecules bind to or 
dissociate from the surface. The binding of the ligand is detected by an optical 
phenomenon called surface plasmon resonance (SPR). In this case, we assessed the 
binding affinity of imatinib to hFGF-1, by analyzing the level of steady state response 
against concentration. The interactions are monitored on a CM5 chip. A glass slide 
coated with thin gold film creates a surface sensor. Dextran acts as a substrate to which 
hFGF-1 was immobilized and provides a hydrophilic environment for the interaction. 
Varying concentrations of imatinib (drug) was injected on a continuous flow of solution. 
SPR causes a reduction in the intensity of light reflected at a specific angle from the 
glass side of the sensor surface. As molecules binds to the sensor surface, the refractive 
index close to the surface changes. This change in SPR angle is directly proportional to 
the change in mass concentration of the material bound [78,79]. The kon and koff rates 
were measured to calculate the dissociation constant (Kd). Using the result from the 
change in refractive index, a sensorgram with binding response on y-axis and time in 
seconds on x-axis was plotted. As appears from Fig. 17, imatinib at varying 
concentrations was capable of strongly binding to hFGF-1 which is in agreement with 
proteolytic digestion and thermal denaturation studies. The Kd was found to be 6.9 M 
and it was further confirmed by repeating the experiments. However Kd of 6.9 M is too 
large for a strong binding and it is unreliable too. And also the kon and koff rates are too 
fast for the instrument to detect and therefore the Kd value might be incorrect. The 
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This means the Biacore instrument cannot detect such quick/strong interaction and 
therefore cannot give us accurate Kd. But results clearly suggest that imatinib binds with 




























Figure 17: Representative measurements of imatinib binding to hFGF-1: (A) SPR 
sensorgrams showing the change in binding response (in RU) upon injection of various 
concentrations of imatinib from 6.25 µM to 100 µM in HBS-EP buffer over hFGF-1 


























Human Fibroblast growth factor-1 was successfully expressed and purified in higher 
yield from bacterial E. coli expression system using affinity chromatography and 
dialysis techniques. Purity and authenticity of the protein was further confirmed by 
SDS-Gel electrophoresis, steady state fluorescence, fast liquid chromatography, and LC-
MS. Results of these studies clearly suggest the purified protein is pure and in its native 
confirmation.  Interaction studies such as, thermal unfolding and proteolytic digestion of 
hFGF-1 in the presence imatinib were conducted. Control experiments without the use 
of ligand were also carried out in order to evaluate the changes in the stability of protein 
in the presence of ligand. In the thermal unfolding experiment, intrinsic fluorescence 
spectra of hFGF-1 were obtained from 20 ºC to 80 ºC. The Tm of hFGF-1 in the presence 
of imatinib was increased by about 6 ºC. In limited trypsin digestion experiment, where 
the hFGF-1 was subjected digestion with protease trypsin, hFGF-1 showed more 
resistance to trypsin in the presence of ligand compared to control. Results of this 
studies confirmed that imatinib binds strongly with hFGF-1 and increase its thermal 
stability and solvent accessibility. In order to further investigate the binding affinity 
between the imatinib and hFGF-1, Biacore, a surface plasmon resonance experiment 
was performed. Results of this study clearly suggest imatinib binds very strongly with 
hFGF-1. The findings of the present study will facilitate research towards understanding 
the hFGF-1 induced angiogenesis. The information acquired from this study will also be 
of substantial use for developing various drugs having structure resemblance to imatinib 




5. FUTURE WORK 
 
The finding that imatinib binds tights with hFGF-1 provides valuable clues for the 
rational design of novel pharmacological approaches to the treatment of inflammatory, 
cardiovascular and oncological disorder. Further binding experiments such as isothermal 
titration calorimetry (ITC) is essential to characterize the dissociation constant, enthalpy 
change of interaction. ITC experiments can be extended to test the competition studies 
between the imatinib against heparin and FGFR, which is very critical to evaluate the 
inhibitory action of hFGF-1 signaling by imatinib. Structural studies always play an 
important role in any drug design. In this context, structural studies are required 
including multi-dimensional nuclear magnetic experiments are required to in order to 
characterize the binding site of imatinib on hFGF-1 and also able to solve the hFGF-1 - 
imatinib binary complex structure. In addition, in vivo experimental studies on hFGF-1 
interaction with imatinib will give information about possibility of interaction under 
physiological conditions. Therefore, the future work will give more insight into the 
interaction between imatinib and hFGF-1, results will give further leads in to anticancer 
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AB Acid Box 
E.coli Escherichia coli 
ER Endoplasmic Reticulum 
ESI-MS Electro-Spray Ionization Mass Spectrometry 
FGFR Fibroblast Growth Factor Receptor 
FPLC Fast Performance Liquid Chromatography 
hFGF Human Fibroblast Growth Factor 
HPLC High Performance Liquid Chromatography 
HSPG Heparin Sulfate Proteoglycans 
IPTG Isopropyl β-D-1-thiogalactopyranoside  
ITC Isothermal Titration Calorimetry 
Kd Dissocation Rate Constant 
L.B Luria Broth 
NaCl Sodium Chloride 
NLS Nuclear Localization Sequence 
NMR Nuclear Magnetic Resonance 
RU Response Units 
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
SPR Surface Plasmon Resonance 
Syt1 Synaptotagmin 
TCA 2,4,6-Trichloroanisole 
TM Transmembrane 
